Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.

ABSTRACT:

Background

Cannabis use disorder is associated with substantial morbidity and, after alcohol, is the most common drug bringing adolescents and adults into treatment. At present, there are no FDA-approved medications for cannabis use disorder. Combined pharmacologic interventions might be particularly useful in mitigating withdrawal symptoms and promoting abstinence.

Objective

The purpose of this study was to evaluate the safety and efficacy of dronabinol, a synthetic form of delta-9-tetrahydrocannabinol, a naturally occurring pharmacologically active component of marijuana, and lofexidine, an alpha-2 agonist, in treating cannabis dependence.

Methods

One hundred fifty six cannabis-dependent adults were enrolled and following a 1-week placebo lead-in phase 122 were rand

SUBMITTER: Levin FR 

PROVIDER: S-EPMC4729291 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature